Abstract
We analyzed over 40 years of bacteriological surveillance data to reveal a 4-fold increase in Group A streptococcal (GAS) meningitis in 2022 compared to the annual average of 1982-2021 (n=5/year). Already 10 GAS meningitis cases occurred in 2023 (until March 13th). Molecular typing revealed that 25 out-of-29 (86%) isolates received in 2022 and 2023 were emm1.0 (Figure 1). WGS analysis of 19 emm1.0 isolates (2019 until 20th December 2022) demonstrated that 15 out-of-19 (79%) isolates belonged to the toxicogenic M1UK lineage. Based on these observations, we urge clinicians to be vigilant regarding clinical sign of meningitis with invasive GAS infections, since this disease manifestation appears to have a higher than expected occurrence due to clonal replacement by the recently-emerged M1UK variant.
Introduction
Streptococcus pyogenes can cause a wide range of invasive infections, collectively referred to as invasive group A streptococcal (iGAS) infections. A rare but severe disease manifestation of iGAS is meningitis, which has an estimated incidence in adults of 0.2 per 1,000,000 persons per year 1,2. Several European countries as well as the United States have observed an increase of iGAS infections in the past months, with shifts in affected age groups and clinical presentations relative to historic observations 3,4. Here we performed an epidemiological assessment of S. pyogenes meningitis cases, defined by culture-positive cerebrospinal fluid (CSF), using over 40 years of national bacteriological surveillance data.
Methods
Active microbiological surveillance and molecular epidemiology of all-cause bacterial meningitis, including S. pyogenes, is performed by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM). We analyzed S. pyogenes isolates cultured from CSF between 1982-2023 (until March 13th). Typing of S. pyogenes has been based on sequence variation in 180 bp of the emm gene and is routinely performed since 2013 according to the Centers of Disease Control and Prevention protocol (https://www.cdc.gov/streplab/groupa-strep/resources.html). To distinguish between the recently-identified toxicogenic M1UK variant and the M1global strains 5, emm1.0 isolates received between 2019 and 20th Dec 2022 were analyzed by whole-genome sequencing (WGS; Illumina HiSeq). In accordance with Dutch law, approval by a medical ethics committee was not deemed necessary since cases were not subject to any actions or rules of conduct. No informed consent was requested and only pseudonymized data were used for the study.
Results
Between 1982 and 2021, the NRLBM received 216 S. pyogenes CSF isolates, with an annual mean of five isolates (range 1-15). In contrast, 19 S. pyogenes CSF isolates were received in 2022, and 10 isolates were received between January 1 and March 13, 2023.
Among the 48 CSF isolates from 2013-2021, 19 different emm (sub)types were distinguished, with emm1.0 being the dominant emm-type at 35% (n=17; Figure 1)6. However, from the 29 S. pyogenes CSF isolates that have been received between 2022 and 13th March 2023, 25 out-of-29 (86%) isolates were emm1.0 (Figure 1). Using WGS analysis for a smaller selection of emm1.0 isolates (2019 until 20th December 2022), 15 out-of-19 (79%) isolates belonged to the toxicogenic M1UK lineage5, with all emm1.0 isolates received from May 2022 onwards representing the M1UK variant. The 15 M1UK isolates originated from different municipalities, spread across the Netherlands. The age distribution of meningitis patients caused by emm1.0 strains was similar in 2022-2023 compared to 2013-2021 (Figure 2).
Number of received S. pyogenes CSF isolates with proportion of emm1.0, 2013-2023 (until March 13th).
Age distribution of S. pyogenes meningitis patients infected with emm1.0 or other emm types in 2013-2021 versus 2022-2023. * Until March 13th 2023.
Discussion
Since 2022, an increase in S. pyogenes meningitis, with strong overrepresentation of the emm1.0 type and M1UK variant, has been observed in the Netherlands. This study considered meningitis patients based on S. pyogenes cultured from CSF to provide a consistent comparison over time. Study limitations include the exclusion of meningitis patients with only a positive S. pyogenes blood culture, resulting in an underestimation of the overall national occurrence of S. pyogenes meningitis, and the small number of CSF isolates with limited patient information, which precluded more in-depth statistical and clinical evaluation. Furthermore, submission bias to the NRLBM may play a role, given the increased general submission of S. pyogenes isolates throughout 2022. Data from other countries are needed to assess whether the here observed increase in S. pyogenes meningitis is more widespread. The strong overrepresentation of emm1.0 among the received CSF isolates underlines the invasiveness of this emm type 5. Moreover, the dominance of the toxicogenic M1UK variant among emm1.0 CSF isolates suggests an extensive replacement of circulating S. pyogenes emm1.0 strains. Detailed clinical studies are required to assess whether iGAS infections caused by the M1UK variant are generally more severe. Clinicians are urged to be vigilant regarding the occurrence of meningitis with S. pyogenes, as this disease manifestation appears to have a higher than expected incidence with the recently emerged M1UK variant.
Data Availability
The mentioned strains are available upon request to the authors.
Acknowledgements
The authors would like to thank Agaath Arends-van ‘t Klooster, Wendy Bril-Keijzers, Ilse de Beer-Schuurman, Jolein Pleijster, and Claudia Burger for their continued contributions as research technicians of the NRLBM (Amsterdam UMCs, Department of Medical Microbiology and Infection Prevention, Amsterdam, The Netherlands). Data are available upon request to the corresponding author with exception of specific patient information which will only be provided in aggregated form. NMvS declares fee for service and consultancy fees directly paid to the institution from MSD and GSK outside the submitted work. NMvS declared royalties related to a patent (WO 2013/020090 A3) on vaccine development against Streptococcus pyogenes (Vaxcyte; Licensee: University of California San Diego with NMvS as co-inventor). NMvS is a member of the Science advisory Board for the ItsME foundation (unpaid) and Rapua te me ngaro ka tau project (paid to institution; Project facilitating Strep A vaccine development for Aotearoa New Zealand). Other authors declare no conflict of interest.
Footnotes
Fixing/formatting of references
